- Home
- PWRL vs CRMD Comparison
PWRL vs CRMD Comparison
Compare PWRL & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PWRL | CRMD |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 658.6M | 695.9M |
| IPO Year | N/A | 2009 |
Fundamental Metrics
Financial Performance| Metric | PWRL | CRMD |
|---|---|---|
| Price | $12.10 | $7.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $14.83 |
| AVG Volume (30 Days) | 121.0K | ★ 920.3K |
| Earning Date | N/A | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 780.00 |
| EPS | N/A | ★ 0.43 |
| Revenue | N/A | ★ $311,709,000.00 |
| Revenue This Year | N/A | $0.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $17.72 |
| Revenue Growth | N/A | ★ 617.03 |
| 52 Week Low | $11.84 | $6.13 |
| 52 Week High | $16.31 | $14.96 |
Technical Indicators
Market Signals| Indicator | PWRL | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 34.56 | 35.80 |
| Support Level | N/A | $7.05 |
| Resistance Level | $13.39 | $7.44 |
| Average True Range (ATR) | 0.85 | 0.37 |
| MACD | -0.10 | -0.11 |
| Stochastic Oscillator | 12.13 | 5.42 |
Price Performance
Historical ComparisonAbout PWRL Powerlaw Corp. Common Stock
Powerlaw Corp is a non-diversified, closed-end management investment company. The Fund's investment objective is long-term capital appreciation. It seeks to achieve its investment objective by investing in the equity and equity-linked securities of a concentrated portfolio of approximately 12 to 15 late-stage technology companies.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.